
FDA Urged to Preserve Biosimilar Naming Conventions
Several groups, including pharmacies, call on FDA to preserve accepted International Nonproprietary Name conventions for biosimilars.
The Generic Pharmaceutical Association (GPhA) is reporting that 32 organizations, including pharmacies and labor unions, have signed a
“These groups understand that the INN approach to biosimilar naming has proven safe and effective in Europe; it has worked in the United States for chemical drugs and currently approved biologics, therefore it should be the standard for U.S. biosimilars," said Ralph G. Neas, president and CEO of GPhA, in a
The letter follows concerns raised by the National Council of Prescription Drug Programs (NCPDP). In a
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.